# Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients

> **NCT00559624** · PHASE1,PHASE2 · COMPLETED · sponsor: **Advancell - Advanced In Vitro Cell Technologies, S.A.** · enrollment: 40 (estimated)

## Conditions studied

- Leukemia, B-Cell, Chronic

## Interventions

- **DRUG:** Acadesine

## Key facts

- **NCT ID:** NCT00559624
- **Lead sponsor:** Advancell - Advanced In Vitro Cell Technologies, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2011-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00559624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00559624, "Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00559624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*